Predicting the complicated neutropenic fever in the emergency department

J M Moon, B J Chun

ABSTRACT

Objectives: The purpose of this study was to identify independent factors that can be used to predict whether febrile neutropenic patients who appear healthy at presentation will develop subsequent complications, using variables that are readily available in the emergency department (ED).

Method: The medical records of 192 episodes in which the patients presented to the ED with neutropenic fever resulting from chemotherapy, with an alert mental state and haemodynamic stability were retrospectively reviewed. Endpoints examined were fever response to administered antibiotics, death or severe medical complications during hospitalisation.

Results: Thirty-eight episodes of neutropenic fever with complicated outcomes were identified from among a total of 192 episodes. Three parameters emerged as independent factors for the prediction of neutropenic fever with complications in the multivariate regression analysis: platelet count (130–450 × 10^9 cells/mm^3), serum C-reactive protein (CRP, 0.1–1 mg/dl) >10 mg/dl and pulmonary infiltration on chest x-ray.

Conclusions: Platelet count, CRP and pulmonary infiltration on chest x-ray at presentation could be used to identify febrile neutropenic patients who will develop complications, and these factors may be useful in making treatment-related decisions in the ED.

Large studies have shown that neutropenic fever after chemotherapy causes death in 4–30% of patients and serious medical complications in 21% of patients. However, it has been suggested that patients with febrile neutropenia are a heterogenous group in terms of medical complications and mortality. Recent advances in the treatment of neutropenic fever have highlighted the value of risk stratification and recommended outpatient treatment for low-risk patients.

The degree and duration of neutropenia have been identified as key factors related to the risk and outcome of infection. However, this finding was of little use to the treating physician because these factors can only be determined retrospectively.

Risk prediction models, including the Talcott model and the Multinational Association of Supportive Care of Cancer risk index scoring system, were developed. However, the Talcott model requires information, such as tumour response to chemotherapy, which is not readily available in the emergency department (ED). It is possible that the patient’s medical records may not be available in the ED because the patient may be new to the institution. The Multinational Association of Supportive Care of Cancer risk index scoring system includes variables that may be graded differently by different physicians, such as tumour burden of illness.

Previous studies identified clinical or laboratory parameters that could serve as independent predictive factors for risk assessment, including age, acute leukaemia and white blood cell count. However, there is a slight limitation in that these factors were not selected as predictive factors in the other studies for the following reasons. First, the conclusions drawn from studies in children cannot be applied to adults as a result of the differences in comorbidity and the dose of chemotherapy administered. Second, the endpoints used in previous studies, such as bacteraemia, serious bacterial infection or clinical complications, were various.

Studies were recently conducted to analyse the usefulness of serum inflammatory markers, such as procalcitonin, IL6 and C-reactive protein (CRP), in the assessment of the risk of febrile neutropenia. However, these studies were primarily concerned with determining whether these inflammatory markers can identify bacteraeia rather than subsequent complications, and the value of the markers in predicting patient outcomes is limited.

Physicians will regard patients with neutropenic fever combined with shock at presentation as being in a critical condition and treat them intensively. It is thus important to avoid undertreating patients with complicated neutropenic fever, even though they may have appeared healthy upon presentation at the ED.

However, to our knowledge, no study has been conducted to identify the objective independent variables that can be easily assessed in the ED and use them to predict which patients with febrile neutropenia and haemodynamic stability at presentation will develop subsequent potentially serious complications.

Therefore, we sought to identify simple independent factors that can predict patients who develop subsequent complications after chemotherapy-induced neutropenic fever.

METHODS

Design

The present study was a retrospective cohort study that was conducted using chart review methodology. This study was approved by our hospital’s institutional review board.

Setting and population

This study was conducted at a single academic tertiary care centre with an annual ED census of 40 000 patients with or without cancer per year.
The hospital is a large urban medical centre and is designated as one of five specialised cancer centres in South Korea.

We used the hospital electronic medical record system to obtain the medical record numbers of the patients enrolled in this study. The patient selection criteria were as follows: patients presenting to the ED with C00–C97 codes (malignant neoplasm) classified according to the International Classification of Diseases, version 10 between March 2004 and December 2007, neutrophil count less than 500 cells/mm³, age older than 18 years and systolic blood pressure greater than 90 mm Hg at presentation. Fever was defined as an oral temperature greater than 38.3°C on a single occasion or greater than 38.0°C for one hour or longer during the first 24 h after admission.14 A total of 254 episodes was identified. However, six episodes presenting to the ED in an altered mental state were excluded. In addition, we excluded nine episodes who underwent radiotherapy before or during the febrile neutropenic episode, 27 episodes who were transferred to other hospitals or our hospital in the middle of treatment for neutropenic fever, 11 episodes who presented with neutropenic fever as an initial clinical manifestation of unrecognised underlying cancer, seven episodes with incomplete data and two episodes with AIDS.

Finally, 192 febrile neutropenic episodes occurring in 168 patients were analysed. Each febrile neutropenic episode was considered to be a new event.

Protocol
The first author assessed whether the patient met the defined criteria for combined fever and chemotherapy-related neutropenia. The first assistant, who was unaware of the purpose of the study, classified each patient as with or without risk of complications during hospitalisation. Later, a second author, who was unaware of the risk classification and had previous experience with data abstraction from electronic medical records, collected the variables such as initial laboratory findings, empirically administered antibiotics and duration of hospitalisation. To test the accuracy of the risk assessment by the first assistant, a second assistant, who was not listed as an author, collected the variables such as initial laboratory findings, empirically administered antibiotics and duration of hospitalisation. There was no disagreement on the risk assignment.

Complicated neutropenic fever was defined when the fever did not resolve within 5 days of starting treatment, in case of death, or in patients with serious medical complications that needed treatment and occurred during hospitalisation.

Measurement
The following data were collected: (1) variables that were readily available at presentation without information about the medical history of the patient and tested for their predictive value, such as age, sex, tumour type, laboratory variables and the interpretation of chest x-ray by a radiologist; (2) other variables related to patients, such as latency to the development of neutropenic fever after recent chemotherapy, previous medical history, prophylactic administration of antibiotics or antifungal agents and presumed site of infection at presentation; (3) variables related to treatment and outcome, including empirically administered antibiotics, microbiological test results, duration of neutropenia and fever, complications, duration of hospitalisation and survival.

The patients were divided according to microbiologically defined infection with or without bacteraemia, clinically defined infection and unexplained fever according to previously published definitions.15

Data analysis
Baseline data on characteristics and outcomes were summarised by frequency tabulation or mean values. Univariate analysis of the association between each covariate and outcome was performed using the χ² test. Continuous variables tested in the univariate analyses were categorised on the basis of clinical arguments according to physician’s judgement or previously published reports. All covariates with p values less than 0.05 were considered sufficient for the inclusion of a variable in a multivariate stepwise logistic regression analysis, with a significance level of p<0.05. Estimated odds ratios and confidence intervals were calculated for all significant variables. All reported p values are two-sided, and all statistical analyses were performed using SPSS version 15.0.

RESULTS
Patient characteristics
A total of 154 episodes without complications and 38 episodes with serious complications was analysed. Table 1 shows the characteristics and demographic data of the 192 episodes.

The mean age in the study group was 53 years. The mean blood pressure was 126.2 mm Hg (SD 16.8) and the temperature at presentation was 37.9°C (SD 1.0). Fifty-nine episodes had haematological malignancies, of which lymphoma (47 episodes) was the most common underlying haematological malignancy, followed by 11 cases of leukaemia and one case of multiple myeloma.

All patients were admitted and treated with empiric broad-spectrum antibiotics as inpatients. A single antibiotic (meropenem, imipenem, cefepime or ceftazidime) was administered to 15% of the patient medical records selected by random sampling. There was no disagreement on the risk assignment.

Complicated neutropenic fever was defined when the fever did not resolve within 5 days of starting treatment, in case of death, or in patients with serious medical complications that needed treatment and occurred during hospitalisation.

Table 1 Clinical characteristics of the 192 episodes of febrile neutropenia

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>Episode</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>53.5 (SD 12.4)</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>70/122</td>
</tr>
<tr>
<td>Underlying cancer, N (%)</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>65 (33.3%)</td>
</tr>
<tr>
<td>Haematological cancer</td>
<td>59 (30.7%)</td>
</tr>
<tr>
<td>Pulmonary cancer</td>
<td>24 (12.5%)</td>
</tr>
<tr>
<td>Gastrointestinal cancer</td>
<td>23 (12.0%)</td>
</tr>
<tr>
<td>Skeletal cancer</td>
<td>6 (3.1%)</td>
</tr>
<tr>
<td>Hepatobiliary cancer</td>
<td>3 (1.6%)</td>
</tr>
<tr>
<td>Other solid tumour</td>
<td>12 (6.3%)</td>
</tr>
<tr>
<td>Comorbidity, N (%)</td>
<td></td>
</tr>
<tr>
<td>Recent surgery (&lt; 6 months)</td>
<td>46 (24.0%)</td>
</tr>
<tr>
<td>Previous neutropenic fever</td>
<td>47 (24.5%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>19 (9.9%)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>5 (2.6%)</td>
</tr>
<tr>
<td>Prophylactic medication, N (%)</td>
<td>24 (12.5%)</td>
</tr>
<tr>
<td>Antibiotic medication</td>
<td>6 (3.1%)</td>
</tr>
<tr>
<td>Duration of fever at presentation &lt; 24 h, N (%)</td>
<td>135 (70.3%)</td>
</tr>
<tr>
<td>Presumed site of infection at presentation, N (%)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>65 (33.3%)</td>
</tr>
<tr>
<td>Unexplained fever</td>
<td>62 (32.3%)</td>
</tr>
<tr>
<td>Pulmonary tract</td>
<td>44 (22.9%)</td>
</tr>
<tr>
<td>Other</td>
<td>21 (10.9%)</td>
</tr>
</tbody>
</table>

14 The mean age in the study group was 53 years. The mean blood pressure was 126.2 mm Hg (SD 16.8) and the temperature at presentation was 37.9°C (SD 1.0). Fifty-nine episodes had haematological malignancies, of which lymphoma (47 episodes) was the most common underlying haematological malignancy, followed by 11 cases of leukaemia and one case of multiple myeloma.

15 All patients were admitted and treated with empiric broad-spectrum antibiotics as inpatients. A single antibiotic (meropenem, imipenem, cefepime or ceftazidime) was administered to 15% of the patient medical records selected by random sampling. There was no disagreement on the risk assignment.

16 Complicated neutropenic fever was defined when the fever did not resolve within 5 days of starting treatment, in case of death, or in patients with serious medical complications that needed treatment and occurred during hospitalisation.

17 The patients were divided according to microbiologically defined infection with or without bacteraemia, clinically defined infection and unexplained fever according to previously published definitions.
the above-mentioned antibiotics in combination with an aminoglycoside. Eighty-three episodes with neutrophil counts less than 100 cells/mm³ received haematopoietic growth factors during hospitalisation.

### Outcome

Nine (5.8%) of the episodes in the group of patients without complications and eight (21.1%) of the episodes in the group of patients with complications had a microbiological pathogen (p = 0.001). In addition, of the 60 episodes who had an unexplained fever, 57 were in the group of patients without complications (p = 0.001). However, there was no difference in the incidence of clinically defined infection between the groups with and without complications.

Neutropenia (2.6 days (SD 2.0) vs 3.8 days (SD 1.9), p = 0.001) lasted significantly longer in the group of patients with complications than in the group of patients without complications. Patients without complications were discharged 6.6 days (SD 4.1) after hospitalisation, whereas patients with complications were hospitalised for 18.2 days (SD 16.8; p = 0.001) and did not have a body temperature greater than 38.3°C at presentation. Therefore, we only enrolled patients who were alert and had systolic blood pressure greater than 90 mm Hg at presentation. In addition, we observed the elevation of body temperature during the first 24 h after presentation, in order to include patients who had taken an antipyretic agent before presentation and did not have a body temperature greater than 38.3°C at presentation.

In the present study, 19.8% of episodes experienced at least one serious medical complication or episode of prolonged fever. Early predictive markers of neutropenic febrile patients who are likely to develop serious complications are thus needed to allow the rapid evaluation and treatment of febrile neutropenia, as in 19.8% of the episodes in our study.

In our study, we excluded parameters that were affected by the subjective judgement of the physician and those that were obtained retrospectively or through detailed analysis of the patient’s medical history, even though these factors were

### Table 3 Univariate analysis of outcomes for patients with neutropenic fever

<table>
<thead>
<tr>
<th>Laboratory findings</th>
<th>Total</th>
<th>Without complications N (154)</th>
<th>With complications N (38)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC &lt;500 cells/mm³</td>
<td>83 (43.2%)</td>
<td>60 (39.0%)</td>
<td>23 (60.5%)</td>
<td>0.016</td>
</tr>
<tr>
<td>Platelets &lt;50 000 cells/mm³</td>
<td>46 (24.0%)</td>
<td>26 (16.9%)</td>
<td>20 (52.6%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Monocytes &lt;100 cells/mm³</td>
<td>92 (47.9%)</td>
<td>66 (42.9%)</td>
<td>26 (68.4%)</td>
<td>0.005</td>
</tr>
<tr>
<td>Neutrophils &lt;100 cells/mm³</td>
<td>115 (59.9%)</td>
<td>91 (59.1%)</td>
<td>24 (63.2%)</td>
<td>0.647</td>
</tr>
<tr>
<td>Lymphocytes &lt;100 cells/mm³</td>
<td>37 (19.3%)</td>
<td>25 (16.2%)</td>
<td>12 (31.6%)</td>
<td>0.032</td>
</tr>
<tr>
<td>Total protein (6–8.3 g/dl) &lt;6.0 g/dl</td>
<td>51 (26.6%)</td>
<td>36 (23.4%)</td>
<td>15 (39.5%)</td>
<td>0.044</td>
</tr>
<tr>
<td>Albumin (3.5–5 g/dl) &lt;3.0 g/dl</td>
<td>25 (13.0%)</td>
<td>17 (11.0%)</td>
<td>8 (21.1%)</td>
<td>0.100</td>
</tr>
<tr>
<td>BUN (8–20 mg/dl) &gt;20 mg/dl</td>
<td>32 (16.7%)</td>
<td>22 (14.3%)</td>
<td>10 (26.3%)</td>
<td>0.075</td>
</tr>
<tr>
<td>Creatinine (0.5–1.2 mg/dl) &gt;1.2 mg/dl</td>
<td>19 (9.9%)</td>
<td>12 (7.8%)</td>
<td>7 (18.4%)</td>
<td>0.049</td>
</tr>
<tr>
<td>CRP (0.1–1.0 mg/dl) &gt;10 mg/dl</td>
<td>78 (40.6%)</td>
<td>52 (33.8%)</td>
<td>26 (68.4%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Positive test for urine nitrates</td>
<td>18 (9.4%);8%</td>
<td>16 (10.4%)</td>
<td>2 (5.3%)</td>
<td>0.332</td>
</tr>
<tr>
<td>Pulmonary infiltration</td>
<td>18 (9.4%)</td>
<td>3 (1.9%)</td>
<td>15 (39.5%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

The normal ranges of complete blood counts are as follows: white blood cells (WBC) (4.8–10.8×10⁹ cells/mm³), platelets (130–450×10⁹ cells/mm³), 2–9% monocytes, 50–75% neutrophils and 20–40% lymphocytes of WBC. BUN, blood urea nitrogen.

**Discussion**

The number of patients who appear healthy at presentation but will develop serious complications and in whom independent variables can predict such an outcome in this group is an important question for emergency medicine physicians. Therefore, we only enrolled patients who were alert and had systolic blood pressure greater than 90 mm Hg at presentation. In addition, we observed the elevation of body temperature during the first 24 h after presentation, in order to include patients who had taken an antipyretic agent before presentation and did not have a body temperature greater than 38.3°C at presentation.

In the present study, 19.8% of episodes experienced at least one serious medical complication or episode of prolonged fever. Early predictive markers of neutropenic febrile patients who are likely to develop serious complications are thus needed to allow the rapid evaluation and treatment of febrile neutropenia, as in 19.8% of the episodes in our study.

In our study, we excluded parameters that were affected by the subjective judgement of the physician and those that were obtained retrospectively or through detailed analysis of the patient’s medical history, even though these factors were
considered to be predictive factors in previous reports. Finally, platelet count, CRP and pulmonary infiltration were shown to have a significant association with outcome. The clear advantage of these significant variables is that there is no observer variability and they can be very readily assessed on presentation.

The initial complete blood cell count had been investigated in several studies of risk assessment. Studies in the field of paediatrics by Rackoff et al., Baorto et al. and Klaassen et al. proposed that the monocyte count with a specific cutoff value was a significant factor in the development of bacteraemia or severe bacterial infection. In a recent prospective study, none of the haematological parameters were found to be independent variables for the prediction of complications in adults with chemotherapy-induced febrile neutropenia. In our study, only platelets less than 50,000 cells/mm$^3$ was predictive of a complicated neutropenic fever. It may be possible that the platelet count acts as a surrogate marker of the host response to inflammation and exposure to activated coagulation factors to accelerate disseminated intravascular coagulopathy before the initiation of therapy.

The level of serum CRP was also recognised as an independent factor in the multivariate model. CRP was sensitive for the prediction of complications in adults with chemotherapy-induced febrile neutropenia before the onset of severe bacterial infection. In a recent prospective study, none of the haematological parameters were found to be independent variables for the prediction of complications in adults with chemotherapy-induced febrile neutropenia. In our study, only platelets less than 50,000 cells/mm$^3$ was predictive of a complicated neutropenic fever. It may be possible that the platelet count acts as a surrogate marker of the host response to inflammation and exposure to activated coagulation factors to accelerate disseminated intravascular coagulopathy before the initiation of therapy.

Provenance and peer review: Not commissioned; externally peer reviewed.

REFERENCE

Pain in the leg after jogging

A 59-year-old woman complained of pain in her left knee. She told us that she had been suffering from osteoarthrosis of the left knee and underwent a medial meniscectomy 8 years ago. She also mentioned that she started exercising 8 weeks ago by jogging. The pain started immediately after one jogging session. We performed an x-ray and a magnetic resonance imaging scan of her left knee (fig 1), which showed osteoarthrosis of the medial knee compartment and a translucent patchy spot in the proximal tibia. The patient was diagnosed as having a stress fracture of her tibia caused by the sudden commencement of jogging. The patient was managed conservatively with an above-the-knee circular polymer resin cast for 6 weeks. The first 2 weeks were non-weight bearing and the remaining 4 weeks were weight bearing. After 6 weeks the patient was symptom free.

S M M de Castro, P Joosse, Ç Unlü, E P H Steller
Department of Surgery, Saint Lucas Andreas Hospital, Amsterdam, The Netherlands
Correspondence to: Dr S M M de Castro, Jan Tooropstraat 164, 1061 AE, Amsterdam, The Netherlands; stevedecastro@gmail.com

Competing interests: None.
Patient consent: Obtained.
Accepted 9 September 2008

Figure 1 (A) Anterior-posterior x ray of the left knee showing osteoarthrosis of the medial knee compartment. Translucent patchy spot of the proximal tibia. (B) Antero-posterior magnetic resonance imaging scan shows bone marrow oedema and a fracture line.
Predicting the complicated neutropenic fever in the emergency department

J M Moon and B J Chun

Emerg Med J 2009 26: 802-806
doi: 10.1136/emj.2008.064865

Updated information and services can be found at:
http://emj.bmj.com/content/26/11/802

These include:

References
This article cites 22 articles, 5 of which you can access for free at:
http://emj.bmj.com/content/26/11/802#BIBL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (84)
Drugs: infectious diseases (287)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/